abstract |
The present disclosure provides an isolated neoantigenic peptide comprises a tumor-specific neoepitope that is capable of binding to MHC-1 to form a MHC-neoantigen complex, a neoantigen binding peptide, T cells comprising TCR or CAR comprising the neoantigen binding peptide, and their use for the immunotherapy of cancer, especially for cancer having a BRAF G469V mutation. |